Stipend and Dates

Up to $15,300. (Multiple payments)

Note: You cannot pick which cohort you go into. The 1st cohort is filled before patients are placed in the next cohort. You must be able to do any of the cohorts. *If you dosed for Part A of this study you cannot participate in Part B. Cohort 3B
Day -17 - This is the LAST day to screen childbearing females or females with tubal ligations. *These females CANNOT screen after this date. Jan 06
Only males and Non-childbearing women can screen after Jan 06. (PMP, Hysterectomy, salpingectomy or oophorectomy)  
Day -2 Admit Jan 21, 2023
* Holter monitoring starts on Day -1 to Day 13 (No electronics = cell phones, computers, TV ) *1st payment within 10 business days after completing Day 7.  
Day 13 Discharge (a payment within 10 business days after this day is completed) Feb 04, 2023
Day 15 Outpatient visit Feb 06
Day 17 Outpatient visit Feb 08
Day 20 Outpatient visit Feb 11
Day 24 Outpatient visit Feb 15
Day 31 Final Outpatient visit (a payment within 10 business days after this day is completed) Feb 22


Click here to make an appointment for NO 0009-0625 Part B

Or call 210-225-5437 for more information

Study Criteria

Healthy non-smoking overweight Males and Females

Age:  18-55

BMI:  25.0 to 34.9 kg/m2

Study Information

Indication: The investigational drug is being developed as a potential treatment for overweight and/ obesity.

Route of Administration: Oral

Washout from previous study: Participation in any clinical study within 30 days before receiving study drug in this study.

Acceptable Birth Control for Females (if Childbearing):  Females of child bearing potential must agree to use a highly effective method of contraception during the study treatment period and until 19 days after the end of the study. Highly effective methods of contraception are listed below:

  • Intrauterine device with male condoms
  • Intrauterine system with male condoms
  • Partner has had a Vasectomy (confirmed by the absence of sperm)
  • Stable Hormonal contraception with approved oral, intravaginal, transdermal, injectable or implantable (and male condoms).
  • Bilateral tubal occlusion/ligation
  • Sexual Abstinence


Females in the following categories are considered non-childbearing:

  • Documented total hysterectomy (removal of uterus), bilateral salpingectomy (removal of both Fallopian tubes), or bilateral oophorectomy (removal of both ovaries)
  • Menopause more than 12 months prior to study entry (stopped having monthly menstrual periods more than 12 months ago).
  • Greater than or equal to 60 years of age


The male participant should use a condom during study treatment and until the end of study.

Study Reminders

  • 8 hours fasting is required for lab work (only water is allowed)
  • If taking medications, bring them to your screening appointment (including prescription, over the counter, herbal supplements and vitamins)
  • Bring a valid, non-expired photo ID with you when you attend your screening visit.  We accept a valid government issued identification card such as a driver's license, state issued ID card or passport.  You will be required to show this same photo ID at all study visits
  • Arrive 30 minutes before your appointment to complete paper work.
NO 0009-0625 Part B
Healthy Overweight Males and Females
Not Currently Screening.
Male or Female
Payment amount
Up to $15,300
18 - 55